Northwestern Mutual Wealth Management Co. Raises Stock Position in DexCom, Inc. $DXCM

Key Points

• Northwestern Mutual Wealth Management Co. has increased its stake in DexCom, Inc. by 69.5%, owning 74,000 shares valued at over $5 million as of the latest SEC filing.
• DexCom reported earnings of $0.48 per share, exceeding analysts' expectations of $0.45, and revenue of $1.16 billion, representing a year-over-year increase of 15.2%.
• Institutional investors hold approximately 97.75% of DexCom's stock, indicating significant confidence from major financial players.

Northwestern Mutual Wealth Management Co. lifted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 69.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 74,000 shares of the medical device company's stock after purchasing an additional 30,339 shares during the quarter. Northwestern Mutual Wealth Management Co.'s holdings in DexCom were worth $5,053,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Golden State Wealth Management LLC lifted its position in DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after buying an additional 264 shares during the last quarter. Private Trust Co. NA raised its holdings in DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after purchasing an additional 335 shares in the last quarter. Farther Finance Advisors LLC raised its stake in DexCom by 29.3% in the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock worth $209,000 after buying an additional 702 shares in the last quarter. Dynamic Advisor Solutions LLC lifted its stake in shares of DexCom by 34.2% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock valued at $357,000 after purchasing an additional 1,333 shares during the period. Finally, Stonebridge Financial Group LLC lifted its position in DexCom by 944.5% during the first quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock valued at $220,000 after buying an additional 2,909 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Price Performance

DXCM stock traded up $0.26 during midday trading on Monday, hitting $75.34. The company's stock had a trading volume of 2,921,932 shares, compared to its average volume of 4,070,578. The firm has a market capitalization of $29.54 billion, a price-to-earnings ratio of 52.32, a price-to-earnings-growth ratio of 1.58 and a beta of 1.48. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25. The company has a 50 day moving average of $82.25 and a two-hundred day moving average of $79.41.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the business earned $0.43 earnings per share. DexCom's revenue for the quarter was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. On average, analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analyst Weigh In

DXCM has been the subject of several recent analyst reports. Raymond James Financial lifted their price target on DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 31st. William Blair upgraded DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. The Goldman Sachs Group assumed coverage on DexCom in a report on Friday, May 30th. They set a "buy" rating and a $104.00 price target on the stock. Argus started coverage on DexCom in a report on Thursday, August 21st. They issued a "buy" rating and a $100.00 price objective for the company. Finally, Morgan Stanley upped their target price on shares of DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, DexCom currently has an average rating of "Moderate Buy" and a consensus target price of $99.89.

Insider Buying and Selling

In related news, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the completion of the sale, the director directly owned 56,621 shares of the company's stock, valued at approximately $4,706,903.73. This trade represents a 4.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the sale, the executive vice president owned 94,102 shares in the company, valued at approximately $7,555,449.58. The trade was a 0.53% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,722 shares of company stock worth $1,306,131 in the last 90 days. Company insiders own 0.32% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.